<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROSTIN  E2- dinoprostone suppository </strong><br>Pharmacia and Upjohn Company<br></p></div>
<h1>Prostin E2<span class="Sup">®</span><br> dinoprostone vaginal <br>suppository</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PROSTIN E2 Vaginal Suppository, an oxytocic, contains dinoprostone as the naturally occurring prostaglandin E2 (PGE2).</p>
<p>Its chemical name is (5Z,11α,13E,15S)-11,15-Dihydroxy-9-oxo-prosta-5,13-dien-1-oic acid and the structural formula is represented below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fae013fc-e199-43f3-86ef-66d34017c534&amp;name=prostin-e2-01.jpg"></div>
<p>The molecular formula is C<span class="Sub">20</span>H<span class="Sub">32</span>O<span class="Sub">5</span>. The molecular weight of dinoprostone is 352.5. Dinoprostone occurs as a white crystalline powder. It has a melting point within the range of 64° to 71°C. Dinoprostone is soluble in ethanol and in 25% ethanol in water. It is soluble in water to the extent of 130 mg/100 mL.</p>
<p>Each suppository contains 20 mg of dinoprostone in a mixture of glycerides of fatty acids.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">PROSTIN E2 Vaginal Suppository administered intravaginally stimulates the myometrium of the gravid uterus to contract in a manner that is similar to the contractions seen in the term uterus during labor. Whether or not this action results from a direct effect of dinoprostone on the myometrium has not been determined with certainty at this time. Nonetheless, the myometrial contractions induced by the vaginal administration of dinoprostone are sufficient to produce evacuation of the products of conception from the uterus in the majority of cases.</p>
<p>Dinoprostone is also capable of stimulating the smooth muscle of the gastrointestinal tract of man. This activity may be responsible for the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that is not uncommon when dinoprostone is used to terminate pregnancy.</p>
<p>In laboratory animals, and also in man, large doses of dinoprostone can lower blood pressure, probably as a consequence of its effect on the smooth muscle of the vascular system. With the doses of dinoprostone used for terminating pregnancy this effect has not been clinically significant. In laboratory animals, and also in man, dinoprostone can elevate body temperature. With the clinical doses of dinoprostone used for the termination of pregnancy some patients do exhibit temperature increases.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<ol>
<li>PROSTIN E2 Vaginal Suppository is indicated for the termination of pregnancy from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period.</li>
<li>PROSTIN E2 is also indicated for evacuation of the uterine contents in the management of missed abortion or intrauterine <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period.</li>
<li>PROSTIN E2 is indicated in the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole).</li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<ol>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to dinoprostone</li>
<li>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span></li>
<li>Patients with active cardiac, pulmonary, renal, or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span></li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1></h1>
<div class="Warning">
<a name="warnings"></a><a name="section-5.1"></a><p></p>
<h2>WARNINGS</h2>
<p class="First">Dinoprostone, as with other potent oxytocic agents, should be used only with strict adherence to recommended dosages. Dinoprostone should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2></h2>
<p class="First">Dinoprostone does not appear to directly affect the fetoplacental unit. Therefore, the possibility does exist that the previable fetus aborted by dinoprostone could exhibit transient life signs. Dinoprostone is not indicated if the fetus in utero has reached the stage of viability. Dinoprostone should not be considered a feticidal agent.</p>
<p>Evidence from animal studies has suggested that certain prostaglandins may have some teratogenic potential. Therefore, any failed pregnancy termination with dinoprostone should be completed by some other means.</p>
<p>PROSTIN E2 Vaginal Suppository should not be used for extemporaneous preparation of any other dosage form.</p>
<p>Neither the PROSTIN E2 Vaginal Suppository, as dispensed nor any extemporaneous formulation made from the PROSTIN E2 Vaginal Suppository should be used for cervical ripening or other indication in the patient with term pregnancy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>1. General precautions</h2>
<p class="First">Animal studies lasting several weeks at high doses have shown that prostaglandins of the E and F series can induce proliferation of bone. Such effects have also been noted in newborn infants who have received prostaglandin E1 during prolonged treatment. There is no evidence that short term administration of PROSTIN E2 Vaginal Suppository can cause similar bone effects.</p>
<p>As in <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>, where the process is sometimes incomplete, abortion induced by PROSTIN E2 may sometimes be incomplete. In such cases, other measures should be taken to assure complete abortion.</p>
<p>In patients with a history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, hypo-or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, cardiovascular disease, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or history of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, dinoprostone should be used with caution.</p>
<p>Dinoprostone administered by the vaginal route should be used with caution in the presence of <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span>, infected endocervical lesions, or <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">acute vaginitis</span>.</p>
<p>As with any oxytocic agent, dinoprostone should be used with caution in patients with compromised (scarred) uteri.</p>
<p>Dinoprostone vaginal therapy is associated with transient <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> that may be due to its effect on hypothalamic thermoregulation. In the patients studied, temperature elevations in excess of 2°F (1.1°C) were observed in approximately one-half of the patients on the recommended dosage regimen. In all cases, temperature returned to normal on discontinuation of therapy. Differentiation of post-abortion <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span> from drug-induced temperature elevations is difficult, but with increasing clinical exposure and experience with PGE2 vaginal therapy the distinctions become more obviously apparent and are summarized below:</p>
<table width="100%">
<col align="left" valign="middle" width="2%">
<col align="left" valign="middle" width="49%">
<col align="left" valign="middle" width="49%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center"><span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">Endometritis</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></th>
<th align="center">PGE2 induced <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">a.</td>
<td align="left">
<span class="Bold">Time of onset:</span> Typically, on third post-abortional day (38°C or higher).</td>
<td align="left">Within 15–45 minutes of suppository administration.</td>
</tr>
<tr>
<td align="left">b.</td>
<td align="left">
<span class="Bold">Duration:</span> Untreated <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> continue and may give rise to other infective pelvic pathology.</td>
<td align="left">Elevations revert to pretreatment levels within 2–6 hours after discontinuation of therapy or removal of suppository from vagina without any other treatment.</td>
</tr>
<tr>
<td align="left">c.</td>
<td align="left">
<span class="Bold">Retention:</span> Products of conception are often retained in the cervical os or uterine cavity.</td>
<td align="left">Elevation occurs irrespective of any retained tissue.</td>
</tr>
<tr>
<td align="left">d.</td>
<td align="left">
<span class="Bold">Histology:</span> Endometrium shows evidence of inflammatory lymphocytic infiltration with areas of necrotic hemorrhagic tissue.</td>
<td align="left">Although the endometrial stroma may be edematous and vascular, there is relative absence of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reaction</span>.</td>
</tr>
<tr>
<td align="left">e.</td>
<td align="left">
<span class="Bold">The uterus:</span> Often remains boggy and soft with <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> over the fundus, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on moving the cervix, on bimanual examination.</td>
<td align="left">Normal uterine involution not tender.</td>
</tr>
<tr>
<td align="left">f.</td>
<td align="left">
<span class="Bold">Discharge:</span> Often associated foul-smelling lochia and <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span>.</td>
<td align="left">Lochia normal.</td>
</tr>
<tr>
<td align="left">g.</td>
<td align="left" colspan="2">
<span class="Bold">Cervical culture</span><br>The culture of pathological organisms from the cervix or uterine cavity after abortion does not, of itself, warrant the diagnosis of septic abortion in the absence of clinical evidence of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. It is not uncommon to culture pathogens from cases of recent abortion <span class="Italics">not</span> clinically infected. Persistent positive culture with clear clinical signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> are significant in the differential diagnosis.</td>
</tr>
<tr class="Last">
<td align="left">h.</td>
<td align="left" colspan="2">
<span class="Bold">Blood count</span><br><span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">Leukocytosis</span> and differential white cell counts are not of major clinical importance in distinguishing between the two conditions, since total WBC's may be increased as a result of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and transient <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span> may also be drug induced.</td>
</tr>
</tbody>
</table>
<p>In the absence of clinical or bacteriological evidence of intrauterine <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, supportive therapy for drug induced <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span> includes the forcing of fluids. As all PGE2-induced <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span> have been found to be transient or self-limiting, it is doubtful if any simple empirical measures for temperature reduction are indicated.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-6.2"></a><p></p>
<h2>2. Laboratory tests</h2>
<p class="First">When a pregnancy diagnosed as missed abortion is electively interrupted with intravaginal administration of dinoprostone, confirmation of intrauterine <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> should be obtained in respect to a <span class="Italics"><span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span></span> for chorionic gonadotropic activity (U.C.G. test or equivalent). When a pregnancy with late fetal intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> is interrupted with intravaginal administration of dinoprostone, confirmation of intrauterine <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> should be obtained prior to treatment.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.3"></a><p></p>
<h2>3. Drug interactions</h2>
<p class="First">PROSTIN E2 may augment the activity of other oxytocic drugs. Concomitant use with other oxytocic agents is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.4"></a><p></p>
<h2>4. Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">Carcinogenic bioassay studies have not been conducted in animals with PROSTIN E2 due to the limited indications for use and short duration of administration. No evidence of mutagenicity was observed in the Micronucleus Test or Ames Assay.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.5"></a><p></p>
<h2>5. Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.5.1"></a><p></p>
<h3>Teratogenic Effects: Pregnancy Category C</h3>
<p class="First">Animal studies do not indicate that PROSTIN E2 is teratogenic, however, it has been shown to be embryotoxic in rats and rabbits and any dose which produces increased uterine tone could put the embryo or fetus at risk. See <a href="#warnings">WARNINGS</a> section.</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.6"></a><p></p>
<h2>6. Pediatric use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequent adverse reactions observed with the use of dinoprostone for abortion are related to its contractile effect on smooth muscle.</p>
<p>In the patients studied, approximately two-thirds experienced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, one-half temperature elevations, two-fifths <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, one-third some <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, one-tenth <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and one-tenth <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>.</p>
<p>In addition, approximately one-tenth of the patients studied exhibited transient diastolic blood pressure decreases of greater than 20 mmHg.</p>
<p>Two cases of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> following the use of dinoprostone have been reported in patients with a history of cardiovascular disease.</p>
<p>It is not known whether these events were related to the administration of dinoprostone.</p>
<p>Adverse effects in decreasing order of their frequency, observed with the use of dinoprostone, not all of which are clearly drug related include:</p>
<table width="85%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless"><tr class="First Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span><br><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span> or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span><br><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Backache</span><br><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Joint inflammation</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> new or exacerbated<br><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> or <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span><br><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span><br><span class="product-label-link" type="condition" conceptid="4244072" conceptname="Vaginal pain">Vaginal pain</span><br><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span><br><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span><br><span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">Endometritis</span><br><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> sensation<br><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span> or <span class="product-label-link" type="condition" conceptid="4269221" conceptname="Vulvitis">vulvitis</span><br><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span><br>Muscular <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramp</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span><br><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Tightness in chest</span></td>
<td align="left">Nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span><br><span class="product-label-link" type="condition" conceptid="195328" conceptname="Rupture of uterus before onset of labor">Uterine rupture</span><br><span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">Breast tenderness</span><br><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span><br><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span><br><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><br><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span><br><span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">Stiff neck</span><br><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span><br><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span><br><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span><br>Hearing impairment<br>Urine retention<br><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span><br><span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">Laryngitis</span><br><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Diaphoresis</span><br><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">Eye pain</span><br><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span><br><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac arrhythmia</span><br><span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">Skin discoloration</span><br><span class="product-label-link" type="condition" conceptid="193261" conceptname="Vaginospasm">Vaginismus</span><br><span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">Tension</span></td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">STORE IN A FREEZER NOT ABOVE −20°C (−4°F) BUT BRING TO ROOM TEMPERATURE JUST PRIOR TO USE.</span></p>
<p><span class="Bold">REMOVE FOIL BEFORE USE.</span></p>
<p>A suppository containing 20 mg of dinoprostone should be inserted high into the vagina. The patient should remain in the supine position for ten minutes following insertion.</p>
<p>Additional intravaginal administration of each subsequent suppository should be at 3- to 5-hour intervals until abortion occurs. Within the above recommended intervals administration time should be determined by abortifacient progress, uterine contractility response, and by patient tolerance. Continuous administration of the drug for more than 2 days is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PROSTIN E2 Vaginal Suppositories are available in foil strips of 5 individually sealed suppositories, NDC 0009-0827-03. Each suppository contains 20 mg of dinoprostone in a mixture of glycerides of fatty acids.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-9.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">STORE IN A FREEZER NOT ABOVE −20°C (−4°F).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fae013fc-e199-43f3-86ef-66d34017c534&amp;name=prostin-e2-02.jpg"></p>
<p>LAB-0063-2.0</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20 mg Suppository <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</h1>
<p class="First"><span class="Bold">Prostin E2<span class="Sup">®</span></span> 20 mg<br>dinoprostone vaginal suppository</p>
<p>MADE IN USA (includes foreign content)</p>
<p>Pharmacia &amp; Upjohn Co., Division of Pfizer Inc, NY, NY 10017</p>
<div class="Figure"><img alt="Principal Display Panel - 20 mg Suppository <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fae013fc-e199-43f3-86ef-66d34017c534&amp;name=prostin-e2-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20 mg Suppository <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Carton</h1>
<p class="First">NDC 0009-0827-03<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">5—20 mg Suppositories</span></p>
<p><span class="Bold">Prostin E2</span><span class="Sup">®</span><br>dinoprostone vaginal<br>suppository</p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<div class="Figure"><img alt="Principal Display Panel - 20 mg Suppository <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fae013fc-e199-43f3-86ef-66d34017c534&amp;name=prostin-e2-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROSTIN  		
					E2</strong><br><span class="contentTableReg">dinoprostone suppository</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0009-0827</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DINOPROSTONE</strong> (DINOPROSTONE) </td>
<td class="formItem">DINOPROSTONE</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0009-0827-03</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017810</td>
<td class="formItem">01/18/1978</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pharmacia and Upjohn Company
							(829076566)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacia and Upjohn Company</td>
<td class="formItem"></td>
<td class="formItem">829076566</td>
<td class="formItem">MANUFACTURE(0009-0827)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f5c08da9-1a0a-41e5-a144-6b5dd7dc9ef9</div>
<div>Set id: fae013fc-e199-43f3-86ef-66d34017c534</div>
<div>Version: 3</div>
<div>Effective Time: 20141028</div>
</div>
</div> <div class="DistributorName">Pharmacia and Upjohn Company</div></p>
</body></html>
